Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001 Authors: Vilde Yuli Stenberg, Rugile Liukaityte, Sandra Kvarsvik Kristiansen, Rina Wangen-Riise, Andrius Kleinauskas, Victoria Dunne, Asta Juzeniene Published: 2025 ABSTRACT AbstractTargeted alpha therapy holds promise for treating advanced prostate cancer, but the interplay between prostate-specific membrane antigen (PSMA) expression, p53 status, and downstream cell fate remains poorly defined. This study evaluates the cytotoxic and cell cycle effects of the alpha-emitting radioligand [212Pb]Pb-AB001 in prostate cancer cell lines with differing PSMA expression and p53 status: C4-2 (PSMA+/TP53-wild-type) and PC-3 PIP (PSMA+++/ TP53-null). [212Pb]Pb-AB001 significantly inhibited proliferation and clonogenic survival in both cell lines in an activity-dependent manner. At 95% clonogenic inhibition, both cell lines exhibited G2-phase arrest, S-phase suppression and reduced mitotic entry on day 1. At higher activities, PC-3 PIP cells showed polyploidy, and features consistent with mitotic catastrophe and senescence. Cytotoxicity was more pronounced in C4-2 3D spheroid models than in 2D monolayers, suggesting contribution of crossfire and bystander effects. Total cell-bound activity, rather than added activity, better predicted radiotoxicity in both TP53-wild-type and TP53-null cell lines, indicating that its therapeutic effect is primarily governed by PSMA-mediated uptake rather than p53 status. These results support the therapeutic potential of [212Pb]Pb-AB001 across cells with varying TP53 status and suggest that combining [212Pb]Pb-AB001 with DNA repair or checkpoint inhibitors may enhance treatment efficacy.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-29785-7.Subject terms: Cancer, Cell biology, Oncology Introduction Prostate cancer remains one of the most prevalent malignancies among men worldwide, and advanced disease often develops resistance to standard treatments1. Targeted radionuclide therapy directed at prostate-specific membrane antigen (PSMA) has emerged as a promising strategy for metastatic castration-resistant prostate cancer (mCRPC)2–6. PSMA is a transmembrane glycoprotein highly overexpressed in most prostate cancers, particularly in advanced stages7. Beta-emitting [177Lu]Lu-PSMA-617 has shown efficacy and gained regulatory approval for mCRPC8, but the majority of responders eventually develop disease progression or relapse9,10. Alpha-emitting radionuclides offer distinct therapeutic advantages over beta emitters due to their high linear energy transfer and short path length in tissue11–13. These properties allow the delivery of densely ionizing radiation over short distances, maximizing tumour cell killing while sparing the surrounding healthy tissue3,11,13–15. The DNA damage response (DDR) is a critical determinant of cellular sensitivity to ionizing radiation12,13,16. It comprises a complex network of mechanisms that detect DNA damage and activate appropriate repair pathways. Key regulators of this response include the kinases Ataxia-telangiectasia mutated (ATM) and Rad3-related (ATR), which coordinate the cellular response, and p53, which is involved in halting the cell cycle or triggering apoptosis following irreparable DNA damage17–20. Some cancer cells can acquire resistance to targeted radionuclide therapy by upregulating DDR pathways or enhancing their DNA repair capabilities20,21. Resistance to PSMA-targeted alpha therapy (TAT) has been associated with mutations in DDR-associated genes22. Nevertheless, the exact mechanisms through which cancer cells acquire resistance to TAT remain poorly understood. Given the high frequency of TP53 mutations in mCRPC23,24, it is essential to evaluate therapeutic responses to TAT in both TP53-wild-type and TP53-deficient cellular models. The p53 protein regulates critical cellular responses to genotoxic stress, including G1/S and G2/M checkpoint control, DNA repair, apoptosis, and senescence25,26. While p53 is not required to initiate G2 arrest, it is essential for maintaining this arrest and preventing premature mitotic entry in the presence of unresolved DNA damage. In its absence, cells may proceed through mitosis with damaged DNA, resulting in genomic instability, polyploidy, or mitotic catastrophe17,25. Alpha-emitting radionuclides deliver densely ionizing radiation and induce complex, difficult-to-repair DNA lesions, and cellular outcomes following such damage can differ markedly depending on p53 status. Comparative studies in p53-proficient and -deficient models are therefore crucial to fully characterize the mechanisms of action and therapeutic potential of TAT. The present study focuses on the PSMA-targeting radioligand [212Pb]Pb-AB001 (previously NG001), which has shown promise in delivering targeted alpha radiation to prostate cancer cells in vitro and in vivo27–29. The aim of this study was to investigate the influence of [212Pb]Pb-AB001 on DNA damage, cell cycle distribution, and cell death modes in two human prostate cancer cell lines with varying PSMA expression levels and reported p53 status. C4-2 exhibits moderate PSMA expression and reported wild-type p5330–34, whereas PC-3 PIP displays high PSMA expression and no detectable p53 expression32,35. By evaluating these effects in different cellular models, we aimed to enhance our understanding of the factors influencing the efficacy of TAT and provide insights into optimising treatment strategies for patients with metastatic prostate cancer. Materials and methods Preparation of 212Pb and radiolabelling of PSMA ligand Lead-212 was produced from 228Th (Eckert & Ziegler, Braunschweig, Germany) via 220Rn emanation using a single-chamber generator36. High purity 212Pb (≥ 99.99%) was eluted from the collector flask with 0.1 M HCl. The 212Pb was used for the radiolabelling of the PSMA ligand AB001 (Medkoo Biosciences, Morrisville, NC, US), as described by Stenberg et al.29 FAPI-46 (targeting fibroblast activation protein (FAP); MedChemExpress, Monmouth Junction, NJ US) was used as a negative control radioligand, as C4-2 and PC-3 PIP cells do not express FAP. AB001 or FAPI-46 was added to the 212Pb solution (0.5 M sodium acetate in 0.1 M HCl, pH 5–6), typically at an effective specific activity of 2 MBq/µg and incubated at 60–90 °C and 450 rpm for 25 min. The radiochemical purity of the radioligand was evaluated using instant thin layer chromatography (Tec-control, model #150–772, Biodex Medical Systems, Shirley, NY, US), and radioligands with purities ≥ 95% were used in subsequent experiments. The 212Pb activity was measured using a Cobra II Autogamma Counter (Packard Instrument Company, Downer Grove, IL, US) with the 50–120 keV counting window and a Capintec CRC-127R radioisotope dose calibrator (Capintec Inc., Ramsey, NJ, US) with calibration number 667 for 212Pb in equilibrium with progenies37,38. Cell lines The human prostate cancer cell line C4-2 (PSMA+, TP53-wild-type)30–33 was obtained from ATCC (ATCC® CRL-3314™ and CRL-1740™, Manassas, VA, US). The PC-3 PIP cell line (PSMA⁺⁺⁺, TP53-null)35,39 was kindly provided by Dr. Martin Pomper (Johns Hopkins University School of Medicine, Baltimore, MD, USA). PC-3 PIP cells are a derivative of the parental PC-3 cell line (AR-negative, PSMA-negative)40,41, engineered to overexpress human PSMA42. Both cell lines were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a humid atmosphere with 5% CO2. In addition, PC-3 PIP cells were supplemented with 2 µg/mL puromycin to ensure stable PSMA expression43. Evaluation of PSMA expression PSMA expression was assessed by flow cytometry using fluorochrome-labelled anti-PSMA antibody Vio® Bright R720 REA408 (130-131-139; 1:50; Miltenyi Biotec, North Rhine-Westphalia, Germany), according to the manufacturer’s recommendations. Briefly, 0.5–1 × 106 cells were incubated with the anti-PSMA antibody or the corresponding REA control antibody in phosphate-buffered saline (PBS) supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA in the dark at 2–8 °C for 10 min. Cells were washed twice, and PSMA expression was analysed using a CytoFlex S Flow Cytometer (Beckman Coulter, Inc., Brea, CA, US). Data analysis was performed with FlowJo 10.10.0 software. Radiotoxicity assessment in clonogenic survival and proliferation assays The radiotoxicity of [212Pb]Pb-AB001 was evaluated using clonogenic survival and proliferation assays. For the clonogenic assay, cells (500–10 000) were seeded in T25 flasks and treated the following day with [212Pb]Pb-AB001 (1.6–100 kBq/mL) at 37 °C for 1 h. The radioligand was replaced with fresh medium, and the cells were incubated until colonies (> 50 cells) were formed in both control and treated groups: 7–11 days for PC-3 PIP cells and 14 days for C4-2 cells. The colonies were fixed with 96% ethanol and stained with 0.4% methylene blue. The colonies were counted, and the survival fractions were normalized to the plating efficiency of the control. Cell survival curves were fitted to a single exponential model (Survival fraction = a × e− bx, where x is the activity and a and b are constants) using SigmaPlot 15.0 software (Systat Software, Inc., San Jose, CA, US). Activities of [212Pb]Pb-AB001 required to reduce clonogenic survival, i.e., fraction of cells that retain the ability to form colonies, to 50% (CI50), 25% (CI75) and 5% (CI95) were determined from the cell survival curves. For the proliferation assay, 0.25 × 106 cells were seeded in T75 flasks and incubated with 3.1–50 kBq/mL of [212Pb]Pb-AB001 at 37 °C for 1 h the following day. The radioligand was replaced with fresh medium, and viable cells were counted at various timepoints until reaching confluence for up to 28 days using Bürker counting chambers (Hycor Biomedical, Ltd., Penicuik, UK). Medium was replaced once a week. Assessment of radioligand binding For assessment of [212Pb]Pb-AB001 binding to C4-2 and PC-3 PIP cells, 1 × 106 cells were seeded in T25 flasks one day prior to 1-h treatment with 1.6–50 kBq/mL [212Pb]Pb-AB001. The cells were detached from the flasks using 1 mM EDTA, collected and washed three times with PBS containing 0.5% w/v BSA. The samples were then measured using the Cobra II Autogamma Counter and the cells were counted to determine the bound activity per cell (µBq/cell). Ligand binding curves were fitted to a one site saturation, ligand binding non-linear regression model using SigmaPlot 15.0 software. Radiotoxicity assessment in a multicellular spheroid model C4-2 spheroids were generated by seeding cells in 1.5% w/v agarose-coated flat bottom 96-well plates (500 cells/100 µL). The plates were centrifuged at 470 × g for 15 min and incubated at 37 ˚C for 5 days to allow spheroid formation. The spheroids were treated with 2–10 kBq/mL of [212Pb]Pb-AB001 at 37 ˚C for 1 h. To evaluate toxicity of non-specifically bound radioligand, PSMA binding sites were pre-blocked with an excess of unlabelled AB001 for 30 min. Following treatment, spheroids were washed 6 times with fresh medium and then incubated at 37 ˚C for 21 days with regular medium changes 2–3 times per week. Spheroid growth was monitored using bright field microscopy with an inverted Axiovert 200 M microscope (Carl Zeiss AG, Baden-Wurttemberg, Germany) and analysed using AxioVision Rel. 4.8 software (Carl Zeiss AG). PC-3 PIP cells form multicellular spheroids44, but are prone to disintegration during washing; therefore, they were excluded from the study due to the requirement for multiple wash steps after radioligand incubation. Evaluation of viability, cell cycle distribution and DNA damage Cells (0.25–1.5 × 106) were seeded in T25 or T75 flasks and treated the following day with 3.1–50 kBq/mL of [212Pb]Pb-AB001 at 37 °C for 1 or 4 h (C4-2 only). Cells were harvested 1 h, 1 day, 3 days and 6 days after treatment for evaluation of viability, cell cycle distribution and DNA damage. For viability assessment, cells were stained with Annexin V FITC (ImmunoTools, Friesoythe, Germany) and 1.9 µg/mL propidium iodide (PI; Sigma Aldrich Norway AS) prepared in Annexin V binding buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2) at room temperature for 10–15 min. To investigate cell cycle distribution and DNA damage, cells were first stained with fixable viability dye FVD-eFluor450 (Invitrogen, Thermo Fisher Scientific) on ice for 60 min. Subsequently, cells were fixed with 100% methanol. After fixation, the samples were washed with PBS containing 0.2% v/v Tween-20 (PBST), and stained with 1 µg/mL primary antibodies: rabbit anti-pS10H3 and mouse anti-pγH2AX (#06-570 and #05-636; Merck Millipore, Darmstadt, Germany) in PBST with 2% v/v FBS and 0.4 mg/mL PureLink RNase A (Invitrogen, Thermo Fisher Scientific) at room temperature in the dark for 60 min. The samples were then washed with PBST and incubated with 2 µg/mL secondary antibodies: donkey anti-rabbit AlexaFluor647-conjugated (#A-31573; Invitrogen, Thermo Fisher Scientific) and goat anti-mouse FITC-conjugated (#F0479; Dako, Agilent Technologies, Santa Clara, CA, US) in PBST with 2% v/v FBS at room temperature for 30 min. Lastly, the samples were stained with 10 µg/mL PI in PBST. All samples were analysed using a CytoFlex S Flow Cytometer with C Flow Plus Software and quantified using FlowJo 10.10.0 software. Detection of senescent cells To detect senescent cells, the CellEvent™ Senescence Green Flow Cytometry Assay Kit (Thermo Fisher Scientific) was used according to the manufacturer’s recommendations. Briefly, PC-3 PIP cells (0.1–1.5 × 106) were seeded and treated the following day with 3.1–25 kBq/mL of [212Pb]Pb-AB001 at 37 °C for 1 h. After 1, 3 and 6 days, cells were harvested and approximately 0.5 × 106 cells were fixed with 2% paraformaldehyde in PBS for 10 min at room temperature, protected from light. After fixation, the cells were washed with 1% BSA in PBS and resuspended in CellEvent™ Senescence Green Probe diluted 1:500 in CellEvent™ Senescence Buffer. The cells were incubated at 37 °C without CO2 for 1.5 h in the dark. After incubation, the cells were washed and resuspended in 1% BSA in PBS. Flow cytometry analysis was performed using the CytoFlex S Flow Cytometer and data were analysed with FlowJo 10.10.0 software. For each activity concentration, an unstained sample was included to account for autofluorescence. The geometric mean fluorescence intensity of each unstained sample was subtracted from that of the corresponding stained sample. Fold change in senescence was then calculated by normalizing the autofluorescence-corrected geometric means to the untreated control group. Senescence was also detected through histochemical staining using the Senescence Cells Histochemical Staining Kit (#CS0030; Merck), as described in the manufacturer’s protocol. Cells (8 000–10 000) were seeded in 6-well plates and treated as described previously. Cells were washed twice with PBS and treated with Fixation Buffer for 6 min at room temperature. Each well was then washed three times with PBS and stained with Staining Solution at 37 °C without CO2 overnight. The Staining Solution was replaced with PBS, and the wells were imaged using a Axiovert 40 CFL Inverted Microscope (Carl Zeiss AG) with AxioVision Rel. 4.5 software (Carl Zeiss AG). Statistical analyses Statistical analyses were performed using SigmaPlot 15.0 software. Groups were compared using a one-way ANOVA with multiple comparisons after normality and equal variance were evaluated by Shapiro-Wilk and Brown-Forsythe tests. Multiple comparison correction methods used were Tukey’s for parametric or Dunn’s for non-parametric evaluation. Groups with low number of samples (< 3) were analysed with non-parametric tests. A p-value of < 0.05 was considered statistically significant. Results PSMA expression PSMA expression levels varied across prostate cancer cell lines (Fig. 1). C4-2 cells exhibited moderate PSMA expression with geometric mean fluorescence intensity of 111-fold higher than the negative control. In comparison, PC-3 PIP cells had a considerably higher PSMA expression profile, with a geometric mean fluorescence intensity of 1688-fold greater than the control. PSMA expression assessed by flow cytometry. Cells (0.5–1 × 106) were stained with a fluorochrome-labelled anti-PSMA antibody Vio® Bright R720 REA408. A corresponding REA control antibody was used as a negative control. Flow cytometry analysis was performed using a CytoFlex S Flow Cytometer, and data were analysed using FlowJo 10.10.0 software. Histograms show representative data from one of three experiments (N = 2–3). Radiotoxicity assessment in clonogenic Inhibition and proliferation assays [212Pb]Pb-AB001 significantly inhibited the clonogenic and proliferative abilities of prostate cancer cells in an activity-dependent manner in both cell lines (Fig. 2a, b). The PC-3 PIP cells (PSMA+++) demonstrated greater radiosensitivity than C4-2 cells (PSMA+), correlating with their higher PSMA expression and increased radioligand binding (Fig. 2c). An activity concentration of 1.4 kBq/mL of [212Pb]Pb-AB001 reduced clonogenic fraction of PC-3 PIP cells by 50% (CI50), while 13.1 kBq/mL was required for a similar reduction in C4-2 cells (Fig. 2a and Suppl. Table 1). Clonogenic fraction, proliferation, and binding assessment of C4-2 and PC-3 PIP cells treated with [212Pb]Pb-AB001 for 1 h. (a) Clonogenic fraction as a function of added activity. CI50 is the activity concentration that reduced the fraction of cell retaining the ability to form colonies by 50%. (b) Proliferation was assessed by measuring viable cell numbers over time after treatment. (c) Binding assessment, showing cell-associated activity as µBq/cell relative to added activity concentration. (d) Clonogenic fraction as a function of total bound [212Pb]Pb-AB001 per cell. Data are presented as mean ± SD from 2–3 independent experiments. Treatment with [²¹²Pb]Pb-FAPI-46 for 1 h did not reduce clonogenic survival at the studied activities, supporting that cytotoxicity in 2D is PSMA-specific rather than due to non-specific radioactivity in the medium (Suppl. Figure 1). At an added activity of 25 kBq/mL, approximately 680 µBq/cell was measured in C4-2 cells, whereas the same cell-bound activity was reached at a much lower 1.6 kBq/mL in PC-3 PIP cells. Similarly, at an added activity of 50 kBq/mL, the total bound activity increased to 970 µBq/cell in C4-2 cells and was obtained already at 3.1 kBq/mL in PC-3 PIP cells (Fig. 2c). Clonogenic fractions plotted against total cell-bound activity (Fig. 2d) revealed that both cell lines responded identically to [212Pb]Pb-AB001 treatment (Fig. 2d). In the proliferation assay, the cell populations were followed over time. Similar growth delays were observed in the two cell lines at activity concentrations of [212Pb]Pb-AB001 that produced comparable levels of clonogenic survival inhibition (~ CI75–CI95; Fig. 2 and Suppl. Table 1). Specifically, for C4-2 cells, 25–50 kBq/mL reduced the number of viable cells, while for PC-3 PIP cells, 3.1–6.3 kBq/mL achieved a similar effect (Fig. 2b). Activity concentrations of 25 and 50 kBq/mL (> CI99) further reduced PC-3 PIP cell viability, with 50 kBq/mL decreasing the viable cell number to less than 1% of the initial cell count by day 21, with re-growth observed by day 28 (Fig. 2b). These findings indicate heterogenous cell populations with a subset of cells retaining proliferative capacity, even when the majority of cells lack the ability to form colonies. Radiotoxicity assessment in a multicellular spheroid model C4-2 spheroids with initial volumes of 35.1 ± 4.8 × 106 µm3 were treated with [212Pb]Pb-AB001 for 1 h. The treatment resulted in a dose-dependent delay in spheroid growth at activity concentrations of 2–10 kBq/mL (Fig. 3). The time for spheroids to reach a volume of 500 × 106 µm3 increased 1.4- to 3.9-fold compared with untreated controls (Suppl. Table 2). Notably, spheroids treated with 10 kBq/mL [212Pb]Pb-AB001 exhibited growth inhibition until day 14, with re-growth observed in some spheroids at day 21 (Fig. 3). In contrast, pre-blocking with an excess of unlabelled AB001 resulted in similar growth as the untreated spheroids, even at the highest activity concentration of [212Pb]Pb-AB001 (Fig. 3 and Suppl. Table 2), highlighting the importance of specific binding in mediating the cytotoxic effects of [212Pb]Pb-AB001. Growth of C4-2 spheroids after 1-h treatment with [212Pb]Pb-AB001 with or without PSMA pre-blocking. (a) Spheroid volume ± SD (one representative experiment, N = 6 spheroids per group). (b) Representative bright field images captured with an inverted Axiovert 200 M microscope with AxioVision Rel. 4.8 software (× 4 magnification, scale bars are 200 μm). Groups in red (a, b) represent spheroids treated with radioligand directly. Groups in blue (a, b) represent spheroids pre-incubated with an excess of unlabelled AB001 to block PSMA sites prior to radioligand treatment. Apoptosis and necrosis Apoptosis and necrosis were assessed in C4-2 and PC-3 PIP cells following treatment with [212Pb]Pb-AB001 (Fig. 4, Suppl. Figure 2). In C4-2 cells, a significant increase in apoptosis was detected on day 6 after treatment at 50 kBq/mL, following both 1 and 4 h incubations (Fig. 4a). Apoptotic fractions rose to ~ 17%, while dead cells exceeded 15% after the 4-h incubation (p < 0.01 and p < 0.001, respectively). Necrosis remained minimal at all tested time points. In contrast, PC-3 PIP cells, exhibited an activity-dependent increase in apoptotic populations at activities ≥ 12.5 kBq/mL, though changes did not reach statistical significance (p > 0.05; Fig. 4b). Dead cells reached ~ 15% at 50 kBq/mL on day 6 (p < 0.05), and necrosis become more evident at higher activities (25–50 kBq/mL), particularly on day 3 (p < 0.05). Apoptotic, dead and necrotic fractions of C4-2 and PC-3 PIP cells after treatment with [212Pb]Pb-AB001. Cells (0.25–1.5 × 106 cells/flask) were treated with [212Pb]Pb-AB001 for 1 h (both cell lines) or 4 h (C4-2 only) and harvested 1, 3 and 6 days after treatment. The samples were stained with Annexin V FITC and propidium iodide and analysed by flow cytometry. Bars represent mean ± SD from 2–4 independent experiments, each based on acquisition of at least 10 000 events per sample. *p < 0.05, **p < 0.01 or ***p < 0.001 versus untreated control. Induction of DNA damage Treatment with ~ CI95 activities of [212Pb]Pb-AB001 (Fig. 2a, Suppl. Table 1) induced significant DNA damage in both C4-2 and PC-3 PIP cells (Fig. 5). C4-2 cells displayed time-dependent increase in DNA damage with 1.4- and 1.9-fold change on day 1 increasing to 1.6- and 2.5-fold on day 3 compared to an untreated control after 1-h and 4-h incubation, respectively. PC-3 PIP cells also displayed a pronounced time-dependent increase in DNA damage, where the fold-change rising from 1.7 on day 1 to 2.2 on day 3. DNA damage induction in C4-2 and PC-3 PIP cells after treatment with [212Pb]Pb-AB001. Cells (0.25–1.5 × 106 cells/flask) were treated with [212Pb]Pb-AB001 for 1 h (both cell lines) or 4 h (C4-2 only). DNA damage was assessed by flow cytometry based on γH2AX signal intensity. (a) Fold-change in the geometrical mean of fluorescence intensity of γH2AX staining relative to untreated control. Cells were harvested 1 and 3 days after treatment and stained with FVD-eFluor450 and anti-γH2AX primary antibody/FITC-conjugated secondary antibody. Bars represent mean ± SD from 2–4 independent experiments. The red dashed line indicates the untreated control. *p < 0.05 or **p < 0.01 versus control. (b) Representative flow cytometry histogram showing γH2AX signal in untreated PC-3 PIP cells (blue) and PC-3 PIP cells treated with 6.3 kBq/mL [212Pb]Pb-AB001 for 1 h analysed on day 3 (red). Cell cycle distribution Cell cycle perturbations were evaluated at ~ CI95 activities of [212Pb]Pb-AB001 (Fig. 2, Suppl. Table 1, Suppl. Figures 3–4) after 1- and 4-h incubation in C4-2 and PC-3 PIP cells (Fig. 6, Suppl. Tables 3–6, Suppl. Figures 3–4). In C4-2 cells, the G2-phase increased by 51% on day 1 post 1h treatment (from 19.5 ± 2.2% to 29.5 ± 5.9%, p < 0.05), while the S-phase decreased by 58% (from 19.0 ± 3.5% to 8.0 ± 3.6%, p < 0.05). The mitotic fraction was reduced compared to control (from 2.9 ± 0.2% to 1.3 ± 0.2%, p < 0.05) and remained low through day 6 (≤ 1.6%). In PC-3 PIP cells, the G2-phase increased by 125% on day 1 (from 26.6 ± 5.9% to 59.8 ± 8.8%, p < 0.05), while the G1 and S phases decreased by 50% (from 50.6 ± 8.8% to 25.2 ± 2.8%, p < 0.05) and 77% (from 19.6 ± 4.7% to 4.5 ± 3.2%, p < 0.05), respectively. A transient increase in mitotic cells was observed on day 3 (from 2.0 ± 0.2% to 3.8 ± 0.2%, p < 0.05), followed by a return to baseline by day 6. Overall, treatment with [212Pb]Pb-AB001 led to a significant G2-phase accumulation in both cell lines. A sustained reduction in mitotic cells was observed only in C4-2 cells, while PC-3 PIP cells showed a tendency toward increased polyploidy at later time points. Cell-cycle distribution of C4-2 and PC-3 PIP cells after treatment with [212Pb]Pb-AB001. Cells (0.25–1.5 × 106 cells/flask) were treated for 1 h (both cell lines) or 4 h (C4-2 only) with [212Pb]Pb-AB001 at the indicated activity concentrations. Cell-cycle phase distribution was assessed by flow cytometry at 1, 3, and 6 days after treatment. (a, b) C4-2 cells treated with 50 kBq/mL for 1 h (a) or 4 h (b), (c) PC-3 PIP cells treated with 3.1–50 kBq/mL for 1 h. Cells were stained with FVD-eFluor450 for viability, anti-pS10H3 primary antibody/AlexaFluor647-conjugated secondary antibody to identify mitotic cells and propidium iodide for DNA content analysis. Data are shown as mean ± SD from 2–6 independent experiments, each based on acquisition of at least 10 000 events per sample. To assess the impact of prolonged exposure, C4-2 cells were also treated with 50 kBq/mL [212Pb]Pb-AB001 for 4 h (Fig. 6b). Under these conditions, the G2-phase increased by 106% on day 1 (from 22.4 ± 1.4% to 46.2 ± 4.4%, p < 0.05), while G1 and S phases were both reduced. The mitotic population remained consistently lower than control levels at all time points (≤ 1.3%, p < 0.05 on days 1 and 3). To further characterize activity-dependent effects, PC-3 PIP cells were treated with increasing activities of [212Pb]Pb-AB001 (12.5–50 kBq/mL) for 1 h (Fig. 6c). On day 1, the G2-phase population increased from 26.0% in untreated controls to 84.0–88.8% across the tested activity range (p < 0.05). G2 fractions remained elevated on day 3 (45.0–61.7%) compared to 21.5% in untreated cells (p < 0.05 for 25–50 kBq/mL). A reduction in S-phase cells was observed at day 1, and G1-phase fractions decreased at all time points after treatment. Mitotic cell fractions declined at early time points (1 h and 1 day) and increased on day 3 at higher activities. The proportion of polyploid cells increased in an activity- and time-dependent manner, from 1 to 1.5% in controls to 7.2–8.6% at day 3 (p < 0.05) and to 15.1–19.9% at day 6 following treatment with 12.5–50 kBq/mL (p < 0.05). Detection of senescent cells [212Pb]Pb-AB001 treatment induced an activity- and time-dependent increase in cellular senescence in PC-3 PIP cells, indicated by the elevated presence of cells positive for senescence-associated β-galactosidase (Fig. 7, Suppl. Figure 5). At 12.5 kBq/mL, the proportion of senescent cells increased from 2.8-fold on day 1 to 13.5-fold on day 6 compared to the untreated control. An activity concentration of 25 kBq/mL resulted in a more pronounced effect, with an increase from 2.7-fold on day 1 to 22.2-fold on day 6. Induction of cellular senescence in PC-3 PIP cells after treatment with [212Pb]Pb-AB001. Cells (0.1–1.5 × 106 cells per flask) were treated for 1 h with [212Pb]Pb-AB001 at the indicated activity concentrations. Senescence was assessed at 1, 3, and 6 days after treatment using complementary flow cytometry and histochemical staining methods. (a) Fold-change in autofluorescence-corrected geometrical mean of CellEvent™ Senescence Green fluorescent signal, which detects β-galactosidase activity in live cells, relative to untreated control, measured by flow cytometry. Bars represent mean ± SD from 2–3 independent experiments, each based on acquisition of at least 10 000 events per sample. *p < 0.05, **p < 0.01 or ***p < 0.001 versus day 1. The red dashed line indicates the untreated control. (b) Representative bright-field images of β-galactosidase histochemical staining for senescent cells at 1, 3, and 6 days after treatment. Increased numbers of blue-stained cells indicate treatment-induced senescence. Scalebar = 20 μm. Discussion Our study demonstrates that [212Pb]Pb-AB001 exerts potent PSMA-mediated cytotoxicity in prostate cancer cells, with biological effects linked to both PSMA expression levels and p53 status. Radioligand treatment significantly reduced clonogenic potential and proliferation in an activity-dependent manner in both C4-2 and PC-3 PIP cells. The stronger response observed in PC-3 PIP cells was attributable to their markedly higher PSMA expression and, consequently, higher levels of cell-bound activity at lower added activity concentrations. Importantly, when survival was plotted against cell-bound activity, both cell lines demonstrated similar activity/cell-response curves (Fig. 2d). This indicates that cytotoxic effect is primarily determined by the amount of radioligand bound rather than the genetic background. Total bound activity per cell is a more reliable predictor of radiotoxicity than added activity, underscoring the need to quantify radioligand uptake when comparing treatment outcomes across cell lines or tumour models. These findings emphasize the necessity of quantifying cellular uptake when comparing radiotherapeutic effects across cell models or patient-derived samples, where receptor density varies widely between patients and tumour types7. Marked differences were also observed between adherent and suspension cultures, with adherent cells displaying higher sensitivity to radioligand exposure. [212Pb]Pb-AB001 significantly reduced clonogenic survival in monolayers, with 50% inhibition at 13.1 kBq/mL in C4-2 cells and 1.4 kBq/mL in PC-3 PIP cells (Fig. 2a). Suspension cultures required higher activity concentrations to reach similar clonogenic inhibition: 29 kBq/mL for C4-2 and 15 kBq/mL for PC-3 PIP cells29. This may reflect improved surface accessibility and more homogeneous distribution of activity in adherent monolayers, whereas cell clustering and free suspension limit uniform exposure. In PC-3 PIP cells, which have high PSMA expression but low radioligand internalisation29, surface binding plays a more significant role in determining radiosensitivity. Conversely, C4-2 cells, characterized by moderate PSMA expression and high internalisation capability, are less affected by surface binding. The stronger DNA damage response observed after 4h incubation compared with 1 h (Fig. 5) can be explained by additional receptor–ligand interactions and increased radioactive decay during the incubation period. PSMA binding sites on the cell surface are limited, and binding typically reaches equilibrium within approximately 1 h45,46. After this point, additional radioligand accumulation can occur through receptor recycling when internalized receptors are returned to the membrane, and PSMA sites become available again, allowing new radioligand molecules to bind46,47. Furthermore, because ²¹²Pb has a half-life of 10.64 h, a markedly larger fraction of the activity decays during 4 h than during 1 h (approximately 23% vs. 6%), leading to more disintegrations occurring while the radioligand is bound or near the cells. Since the cells were grown as adherent monolayers, unbound activity in the medium remains in close proximity to the cell layer. In C4-2 multicellular spheroids, lower activity concentrations of [212Pb]Pb-AB001 were effective to suppress growth over prolonged periods, compared to single cells in monolayer, suggesting that crossfire and bystander effects enhance therapeutic efficacy in spatially complex tumour models. Spheroids treated with 10 kBq/mL showed significant growth inhibition up to day 21 (Fig. 3), whereas single cells treated with 25–50 kBq/mL experienced only a temporary growth delay, lasting up to 15 days (Fig. 2b). C4-2 spheroids have an initial volume of approximately 35 × 106 µm3 (diameter 300–400 μm), around 11 000 cells (with diameters of around 18 μm) and are densely packed. Alpha particles emitted by 212Bi and 212Po travers distances of around 60–80 µm48, allowing them to induce DNA damage in both targeted and neighbouring cells through crossfire effect, leading to significant growth inhibition. Conversely, in the 2D monolayer culture, cells are spread in a single layer with distances of approximately 160 μm between them (assuming an even distribution of cells in the flask and cell diameters of 18 μm), limiting the spatial reach of emitted alpha particles49. Thus, the primary effect is restricted to the directly targeted cells with minimal impact on neighbouring cells due to the limited range of alpha particles. In addition, the bystander effect that occurs when unirradiated cells exhibit cytotoxic effects due to signals from nearby irradiated cells may be more pronounced in spheroids with cell-cell interactions compared to single cells13. A study evaluating the efficacy of [212Pb]Pb-TCMC-chOI-1 in 2D monolayers and 3D spheroids of two bladder cancer cell lines (KU-19-19 and 647-V)50 reported a similar pattern to what we observed in C4-2 cells, illustrating how 3D architecture can result in an amplified effect of alpha particles. The spheroid model exhibits physiologically relevant cell-cell and cell-matrix interactions, heterogeneity and structural complexity, which more accurately mimics the tumour microenvironment. Thus, these findings suggest that lower activities of [212Pb]Pb-AB001 could be particularly effective against metastatic lesions with dense cellular organisation, whereas higher activities are required for treatment of circulating cancer cells. DNA damage analysis showed a sustained induction of γH2AX signal in both cell lines (Fig. 5). These results confirm that [212Pb]Pb-AB001 generates substantial and persistent DNA damage. Importantly, the use of flow cytometry enabled rapid detection of DNA damage across cell populations, providing a robust and time-efficient method to assess treatment-induced genotoxicity. Cell cycle profiling revealed that [212Pb]Pb-AB001 treatment led to a marked G2-phase accumulation in both prostate cancer cell lines (Fig. 6). This was accompanied by a substantial, time- and activity-dependent decrease in the S-phase fraction, particularly evident at higher activity concentrations in PC-3 PIP cells. These observations indicate a robust blockade of DNA synthesis and cell cycle progression, likely reflecting activation of the G2/M checkpoint in response to alpha particle-induced DNA damage. A similar response was reported by Yong et al.51,52, where HER2-targeted [212Pb]Pb-TCMC-trastuzumab in LS-174T (p53 wild-type) human colorectal adenocarcinoma xenografts led to sustained G2/M arrest and near-complete suppression of S-phase for at least four days. Collectively, these findings suggest that G2-phase accumulation coupled with S-phase suppression is a characteristic feature of ²¹²Pb-based TAT across different tumour types and targeting platforms. Despite similar overall trends, the downstream effects of [212Pb]Pb-AB001 diverged between the two prostate cancer models. In C4-2 cells, which reportedly express wild-type p5332,33, G2 arrest was accompanied by a decrease in mitotic index and negligible polyploidy (Fig. 6a, b), suggesting that cells were effectively halted before mitotic entry. In contrast, PC-3 PIP cells, which are reported to lack p53, exhibited persistent G2-phase accumulation but also showed increased mitotic activity and a pronounced rise in polyploidy at later time points (Fig. 6c). This suggests that these cells may bypass G2 arrest and enter mitosis with unrepaired DNA or undergo endoreduplication. Such outcomes are consistent with the known checkpoint adaptation behaviour of p53-deficient cells exposed to DNA damage53,54. Senescence analysis confirmed an activity-dependent increase in β-galactosidase-positive cells in PC-3 PIP cultures (Fig. 7), which peaked on day 6 post-treatment. The induction of senescence may reflect an alternative fate for cells escaping mitotic catastrophe. These results highlight that while both prostate cancer models exhibit G2-phase arrest and reduced S-phase following [212Pb]Pb-AB001 treatment, their downstream responses diverge significantly, suggesting that these responses might depend on TP53 status. In C4-2 cells (TP53 wild-type), apoptosis was induced (Fig. 4), particularly at higher activity levels and prolonged exposure, consistent with activation of canonical p53-mediated DNA damage response pathways. In contrast, PC-3 PIP cells (TP53-null) showed limited apoptosis, however they presented hallmarks of mitotic catastrophe, including increased mitotic index, polyploidy, and enlarged cell morphology, followed by senescence (Figs. 4, 6 and 7). These findings support that while p53 is not required to initiate G2 arrest, it is essential for maintaining checkpoint fidelity and preventing mitotic entry with unresolved DNA damage. Without p53, cells may escape arrest, propagate genomic instability, and undergo p53-independent death pathways25,26. Importantly, these mechanisms reinforce the capacity of high linear energy transfer alpha particles to induce diverse cytotoxic outcomes including apoptosis, mitotic catastrophe, and senescence, depending on the genetic makeup of the target cells. Since TP53 mutations are prevalent in mCRPC23,24, the ability of [212Pb]Pb-AB001 to trigger mitotic catastrophe and cell death in TP53-deficient cells supports its potential to overcome resistance and remain effective across genetically diverse tumours. Delayed apoptosis or senescence response supports the idea that therapeutic efficacy of [212Pb]Pb-AB001 extends beyond immediate cytotoxicity and may involve long-term growth arrest in surviving cells. One of the limitations of this study is that the functionality of p53 in the C4-2 cell line was not assessed directly. Although previous studies have demonstrated functional p53 signaling in C4-2 cells,30–33 the results presented in this study cannot be solely attributed to p53 activity without such experimental confirmation and further mechanistic exploration. Another important limitation of this study is that no correlation was established between cytotoxicity or cell cycle effects and the absorbed physical dose, in either 2D or 3D models. This reflects the complexity of accurate dosimetry in these experimental systems and makes extrapolation to the clinical setting or comparison with other preclinical studies challenging. Future research should explore the molecular mechanisms underlying the observed G2 cell cycle arrest and DNA damage could provide insights into the specific pathways affected by [212Pb]Pb-AB001 therapy. This could involve detailed analyses of checkpoint signalling, DNA repair processes and apoptotic pathways. Our data also support the rationale for combining [212Pb]Pb-AB001 with agents targeting DNA repair, cell cycle checkpoints or senescent cells. Inhibition of ATR, CHK1/2, or WEE1 may sensitize tumour cells to alpha radiation by abrogating G2 arrest and enhancing mitotic catastrophe55. Such strategies may be particularly effective in tumours with DDR defects or TP53 mutations. Conclusions This study demonstrates the potent, PSMA-dependent cytotoxicity of [212Pb]Pb-AB001 in prostate cancer models. Differences in treatment response between 2D and 3D cultures and between cells with reportedly different TP53 status underscore the influence of both tumour architecture and genetic background on therapeutic outcomes. Both C4-2 and PC-3 PIP cells exhibited G2-phase arrest and S-phase reduction following treatment. However, downstream effects diverged: C4-2 cells underwent apoptosis, while PC-3 PIP cells showed signs of mitotic catastrophe and senescence, outcomes that might be attributable to their p53 status. These findings reinforce the ability of [212Pb]Pb-AB001 to induce multiple forms of cell death. The delayed induction of apoptosis and senescence further suggests that [212Pb]Pb-AB001 may exert long-term therapeutic effects beyond initial cytotoxicity. These results underscore the importance of incorporating structural and genetic tumour complexity in preclinical evaluations and pave the way for future combination strategies. Co-treatments with agents targeting cell cycle regulation, DNA repair or senescent cells, such as checkpoint inhibitors, radiosensitizers, DNA repair inhibitors or senolytic agents may enhance therapeutic efficacy by promoting lethal outcomes in G2-arrested, repair-deficient cells or senescent cells. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The ligand AB001 was supplied by ARTBIO (Oslo). The authors acknowledge Elisabeth Wiig (Department of Radiation Biology, Oslo University Hospital, Oslo) for technical assistance with 212Pb harvesting and cell preparations. The authors would like to thank Nick Pullen (ARTBIO) and Ada Repetto-Llamazares (ARTBIO) for reviewing later versions of the manuscript. Author contributions The authors V.Y.S., R.L., S.K.K. and A.J. contributed to the study conception and design. Experimental execution and analysis were performed by all authors. V.Y.S. and A.J. wrote the first draft of the manuscript, and all reviewed several versions of the manuscript. All authors read and approved the final manuscript. Funding The research was funded by the TARACAN project (Radforsk, Oslo), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP), ARTBIO AS (Oslo) and Prostate Cancer UK Career Acceleration Fellowship (Grant Number TLD-PF21-001). Data availability The datasets generated during the current study are available in the Zenodo repository, 10.5281/zenodo.17550519. Declarations Competing interests Two authors (V.Y.S. and R.L.) were employees of ARTBIO AS at the time the work was conducted,. All other authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Vilde Yuli Stenberg and Rugile Liukaityte. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated during the current study are available in the Zenodo repository, 10.5281/zenodo.17550519.